证券代码：603014 证券简称：威高血净 公告编号：2025-030 山东威高血液净化制品股份有限公司 关于 2025 年限制性股票激励计划授予结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、限制性股票授予情况 根据山东威高血液净化制品股份有限公司（以下简称"公司"）2025 年第一次临 时股东大会授权，公司于 2025 年 9 月 16 日召开第二届董事会第十五次会议，审议通 过了《关于向 2025 年限制性股票激励计划激励对象授予限制性股票的议案》，确定 向符合授予条件的 120 名激励对象授予 636 万股限制性股票，授予价格为人民币 19.77 元/股，公司薪酬与考核委员会对本股权激励计划相关事项发表了核查意见。 （一）公司本激励计划限制性股票实际授予情况如下： 5、股票来源：公司向激励对象定向发行的本公司人民币 A 股普通股股票。 | 姓名 | 职务 | 获授的限制性 | 占本激励计划拟 | 占本激励计划草案 | | --- | --- | --- | --- | --- | | | ...

Core Viewpoint - Shandong Weigao Blood Purification Products Co., Ltd. announced the results of its 2025 restricted stock incentive plan, granting 6.36 million shares at a price of 19.77 yuan per share, aimed at enhancing employee motivation and long-term performance [1] Group 1: Incentive Plan Details - The company determined to grant 6.36 million restricted shares to 120 incentive recipients [1] - The grant price is set at 19.77 yuan per share, with the stock sourced from a directed issuance of A-share common stock [1] - The maximum validity period of the incentive plan is 48 months, with a lock-up period starting from the registration date and a minimum gap of 12 months before the first release of restrictions [1] Group 2: Financial Implications - The registration was completed on September 29, raising 125.7 million yuan for liquidity support [1] - The equity structure will see an increase of 6.36 million restricted shares [1] - The cost of the incentive plan will be accounted for in expenses, which will impact net profit in various years [1]

Core Viewpoint - The Chinese blood dialysis medical device market is experiencing steady growth, with a CAGR of 5.67% from 2019 to 2023, and an expected CAGR of 21.52% from 2023 to 2027 [1] Group 1: Market Growth - The demand for dialysis is steadily increasing due to the rapid growth of ESRD patient numbers, with the number of patients undergoing blood and peritoneal dialysis rising from 579,000 and 95,000 in 2018 to 917,000 and 153,000 in 2023, respectively [1] - The market for blood dialysis machines, blood dialysis devices, and blood dialysis tubing has CAGRs of 1.56%, 5.38%, and 8.97% from 2019 to 2023, with expected CAGRs of 22.23%, 20.83%, and 28.94% from 2023 to 2027 [1] - The peritoneal dialysis fluid market is also growing steadily, with an expected CAGR of 16.0% from 2022 to 2026 [1] Group 2: Supply and Demand Dynamics - The supply side is characterized by an increasing number of companies in the blood purification consumables sector, with domestic manufacturers leading the market [1] - Industry policies are supporting the development of the blood purification sector, and centralized procurement is enhancing market concentration [1] Group 3: International Expansion and Service Development - Domestic blood dialysis manufacturers are in the process of accelerating their overseas market expansion, with companies like Sanwa and Weigao Blood Purification increasing their international sales [2] - The global leader, Fresenius Medical Care, generates about 70% of its revenue from the U.S. and has a well-established global network, indicating potential for domestic companies to develop similar service-oriented business models [2] Group 4: Investment Recommendations - Three investment themes are highlighted: 1) Companies with high overseas potential, such as Sanwa, Baolite, Weigao Blood Purification, Sanxin Medical, and Tianyi Medical [3] 2) Companies with a continuously improving product matrix, including Weigao Blood Purification and Sanwa [3] 3) Companies with strong single product competitiveness, such as Weigao Blood Purification, Sanwa, Jianfan Biological, Sanxin Medical, and Tianyi Medical [3]

Group 1: Blood Dialysis Industry - The blood dialysis industry in China is experiencing stable growth, with a market size CAGR of 5.67% from 2019 to 2023, and an expected CAGR of 21.52% from 2023 to 2027 [6][7] - The demand for dialysis is driven by the rapid increase in the number of ESRD patients, which rose from 57.9 thousand in 2018 to 91.7 thousand in 2023 for blood dialysis [6][7] - Investment recommendations focus on three main lines: companies with high overseas potential (e.g., Shanyishan, Baolite, Weigao Blood Purification), companies with a complete product matrix (e.g., Weigao Blood Purification, Shanyishan), and companies with strong single product competitiveness (e.g., Weigao Blood Purification, Shanyishan, Jianfan Biological) [6][7] Group 2: Neurovascular Medical Devices Industry - The neurovascular medical device market in China is projected to grow from 4.9 billion yuan in 2019 to 37.1 billion yuan by 2030, with a CAGR of 20.2% [10][11] - The number of ischemic stroke surgeries in China is expected to increase from 45.8 thousand in 2019 to 881.3 thousand by 2030, reflecting a CAGR of 30.8% [10][11] - Recommended companies include Xianjian Technology, Xinmai Medical, and Huatai Medical, focusing on various aspects of neurovascular intervention [10][11] Group 3: Computer Industry - Tencent's launch of the Hunyuan Image 3.0 model is expected to significantly enhance AI application development and cloud computing demand [13][15] - The model integrates multiple modalities, improving semantic understanding and knowledge reasoning capabilities, which will drive the growth of AI applications across various industries [13][15] - Related investment targets include IDC, server technology, and computing chips [15] Group 4: Electronics Industry - Siwei's revenue for the first half of 2025 is projected to reach 3.786 billion yuan, with a year-on-year growth of 54.11%, driven by significant growth in automotive electronics [16][18] - The company is expanding its presence in high-end applications, particularly in the automotive sector, where revenue increased by 108% year-on-year [17][18] - Investment forecasts for Siwei suggest revenues of 8.06 billion, 10.22 billion, and 12.23 billion yuan from 2025 to 2027 [18] Group 5: Textile and Apparel Industry - Laofengxiang's revenue declined by 16.52% in the first half of 2025 due to high gold prices, but the company is focusing on product innovation and brand upgrades to enhance competitiveness [24][26] - The company is expanding its marketing network, with a total of 5,550 outlets by mid-2025, and is implementing strategies for online and offline integration [25][26] - Future earnings per share are projected to be 3.39, 3.71, and 4.01 yuan from 2025 to 2027, indicating a potential recovery [26]

Core Viewpoint - The company has successfully redeemed structured deposit products totaling 384 million RMB, generating a return of 1.0275 million RMB from the investment of temporarily idle raised funds [2][3]. Group 1: Cash Management and Redemption - The total amount redeemed in this period is 384 million RMB [2]. - The structured deposit products were purchased from various banks, including Shanghai Pudong Development Bank, Minsheng Bank, and others, with specific amounts of 100 million RMB, 54 million RMB, 40 million RMB, and 190 million RMB respectively [3]. - The total principal recovered from these investments is 384 million RMB, with total earnings amounting to 1.0275 million RMB [3]. Group 2: Authorization and Remaining Balance - As of the announcement date, the company has a remaining balance of 30 million RMB in temporarily idle raised funds for cash management, which is within the authorized limit set by the board of directors [3].

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ·本期赎回金额：38,400 万元。 ·赎回理财产品名称：结构性存款。 ·履行的审议程序：山东威高血液净化制品股份有限公司（以下简称"威高血 净"或"公司"）于 2025 年 5 月 27 日召开了第二届董事会第十一次会议和第二届监 事会第八次会议，审议通过了《关于使用部分暂时闲置募集资金进行现金管理的议 案》，同意公司（含子公司，下同）在确保不影响募集资金项目建设和募集资金使用 的情况下，使用最高不超过人民币 74,000 万元（含本数）的暂时闲置募集资金进行 现金管理，增加公司收益，为公司及股东获取投资回报。 一、本次现金管理到期赎回情况 2025 年 6 月 9 日，公司使用暂时闲置募集资金向上海浦东发展银行威海分行购 买了金额为 10,000 万元人民币的结构性存款产品；2025 年 6 月 19 日，公司使用暂 时闲置募集资金向民生银行威海分行购买了金额为 5,400 万元人民币的结构性存款 产品；2025 年 8 月 4 日，公司使用暂时 ...

Group 1 - The core viewpoint of the news is that Weigao Blood Purification experienced a decline in stock price and trading volume on September 22, with a net financing outflow [1] - On September 22, Weigao Blood Purification had a financing buy amount of 6.24 million yuan and a financing repayment of 8.39 million yuan, resulting in a net financing buy of -2.15 million yuan [1] - As of September 22, the total balance of margin trading for Weigao Blood Purification was 104 million yuan, accounting for 7.04% of its circulating market value [1] Group 2 - As of June 30, the number of shareholders for Weigao Blood Purification was 31,400, a decrease of 47.45% compared to the previous period [2] - The average circulating shares per person increased by 90.29% to 1,213 shares [2] - For the first half of 2025, Weigao Blood Purification achieved an operating income of 1.765 billion yuan, a year-on-year increase of 8.52%, and a net profit attributable to shareholders of 220 million yuan, a year-on-year increase of 10.11% [2]

Group 1 - The core point of the announcement is the approval of adjustments to the 2025 restricted stock incentive plan, including changes to the list of recipients and the number of shares granted [2][12][13] - The second board meeting was held on September 16, 2025, with all nine directors present, and the meeting followed legal and regulatory procedures [2][3] - The board approved the adjustment of the incentive plan, reducing the number of recipients from 124 to 120 and the number of shares from 6.65 million to 6.36 million [12][13] Group 2 - The restricted stock grant date is set for September 16, 2025, with a total of 6.36 million shares granted to 120 recipients at a price of 19.77 yuan per share [18][19][26] - The adjustments were made due to some recipients voluntarily reducing or forfeiting their entitlements, ensuring the plan's smooth implementation [13][22] - The board's compensation and assessment committee confirmed that the adjustments comply with relevant regulations and will not materially affect the company's financial status or operating results [14][15][26]

Group 1 - The company announced the approval of a restricted stock incentive plan during the 15th meeting of the second board of directors held on September 16, 2025 [1] - The number of restricted stocks granted is 6.36 million shares, with a total of 120 recipients [1] - The grant price for the restricted stocks is set at 19.77 yuan per share [1]

2、上述任何一名激励对象通过全部有效期内的股权激励计划获授的本公司股票均累计未超 过公司股本总额的 1.00%。公司全部在有效期内的股权激励计划所涉及的标的股票总数累计未超 过公司股本总额的 10.00%。激励对象因个人原因自愿放弃获授权益的，由董事会对授予数量作 相应调整。 3、本激励计划涉及的授予激励对象不包括公司独立董事、监事、单独或合计持有公司 5% 以上股份的股东或实际控制人及其配偶、父母、子女。 山东威高血液净化制品股份有限公司 2025 年 9 月 17 日 山东威高血液净化制品股份有限公司 2025 年限制性股票激励计划授予激励对象名单 山东威高血液净化制品股份有限公司（以下简称"公司"或"本公司"）2025 年 限制性股票激励计划（以下简称"本激励计划"）的激励对象名单及授出权益分配情 况如下： | 姓名 | 职务 | 获授的限制性股票 | 占本激励计划拟授出 | 占本激励计划草案 公布日股本总额比 | | --- | --- | --- | --- | --- | | | | 数量（万股） | 权益数量的比例 | | | | | | | 例 | | 宋修山 | 董事长 | 18.00 | ...